Jonathan Klamkin

CEO Jonathan Klamkin sold 20,000 shares (89.3% of holdings) across 5 separate sales for $500,660.78 under 10b5-1 plan

Jonathan Klamkin, Chief Executive Officer, executed 5 separate sales on 2026-06-01 totaling 20,000 shares for $500,660.78 at prices ranging from $22.19 to $26.25, reducing his holdings from 22,403 to 2,403 shares (an 89.3% reduction). This transaction was part of a pre-arranged 10b5-1 trading plan adopted on 2025-12-03, meaning it was scheduled and not discretionary. Aeluma is operating at a significant loss with a net income of $-1,800,000 ($-1.8M) on quarterly revenue of $1,222,000 ($1.2M), despite strong annual revenue growth of +407.9%, and the CEO's near-complete exit of his position warrants investor attention given the company's unprofitable state and the magnitude of the stake reduction.

CEO Klamkin sells 50,000 shares (50.0K shares) at avg $18.05, stock now $15.72; company unprofitable with $-1.9M net income.

Jonathan Klamkin, Chief Executive Officer of Aeluma, executed 2 separate sales totaling 50,000 shares for $902,599.70 at an average price of $18.05 on 2026-03-04. The stock has since declined to $15.72, trading at -34.6% from its 52-week high of $24.04. Fundamentally, the company reported quarterly revenue of $1,272,000.00 and net income of $-1,853,000.00, and was unprofitable over its most recent full fiscal year. Klamkin's cross-ticker track record shows 1 prior sell with a 90d well-timed rate of 100.00%, and his sole prior trade at ALMU (a sell on 2025-08-14) yielded -25.5% over 90 days. The sale reduces his holdings from 1,479,398 shares to 1,429,398 shares, representing a -3.4% reduction in his position size.

CEO Klamkin sold 150,000 shares at $18.85; stock now down to $18.10, -24.7% from 52-week high of $24.04

Jonathan Klamkin, Chief Executive Officer, sold 150,000 shares (9.2% of pre-transaction holdings) at $18.85 per share on August 14, 2025, reducing his stake to 1,479,398 shares. The sale occurred at a price point that now sits 3.9% above the current price of $18.10, positioning the trade in the upper-middle range of the 52-week window ($2.57–$24.04). The timing coincides with a company in substantial growth mode (annual revenue growth of +375.1%) but emerging from prior losses into recent profitability (latest quarter: $1.5M net income on $1.3M revenue), introducing execution risk and potential valuation volatility. The sale size and retention of 1.48M shares suggest the CEO maintains material exposure despite the reduction.